3 results about "Polyamine metabolism" patented technology

This invention relates to a hybrid tulip tree LhSAMDC gene and its applications, belonging to the field of genetic engineering technology. The CDS nucleotide sequence of the LhSAMDC gene described in this invention is shown in SEQ ID NO.1, and the encoded adenosine methionine decarboxylase plays a key role in plant polyamine metabolism. This invention also provides primer pairs (SEQ ID NO.2 and SEQ ID NO.3) for amplifying this gene and a plant expression vector containing this gene. Experiments using transgenic Arabidopsis thaliana show that overexpression of the LhSAMDC gene significantly increases plant biomass, plant height, leaf SPAD value, and stress resistance. This invention provides a new technical means for plant breeding, which can be used to cultivate new plant varieties with stronger growth vigor, higher biomass, and better stress resistance, and has broad application prospects.

The invention discloses application of a substance for inhibiting polyamine synthesis in preparation of a medicine for treating or relieving endometrial cancer. According to experimental verification of an endometrial cancer cell model and an animal model, it is found that high-fat culture promotes rise of endometrial cancer cell ODC1 and accumulation of polyamine metabolites; mouse serum polyamine metabolites can be up-regulated by feeding the bilateral ovariectomy mouse with high fat; oA-induced polyamine metabolite accumulation and invasion and migration of endometrial cancer cells can be inhibited by knocking down the ODC1; in an animal model, ODC1 is knocked out, and transplantation tumor growth and lymph node metastasis promoted by high fat can also be inhibited by applying an ODC1 inhibitor DFMO. The DFMO can improve the sensitivity of endometrial cancer patients which are resistant to chemotherapeutic drugs. The invention finds that the serum polyamine can be used as a target for developing a medicine for treating or relieving endometrial cancer, and can also be used as a marker for grouping endometrial cancer patients of mammals.

This invention proposes the application of MTA targeting SMS in the preparation of anti-intraocular inflammation products, relating to the biomedical field. Specifically, MTA, as an active molecule, inhibits inflammatory signaling pathways and improves RPE / external blood-retinal barrier damage by targeting and binding to SMS and remodeling polyamine metabolism. Remodeling polyamine metabolism involves MTA targeting and binding to SMS, inhibiting its enzymatic activity and / or expression, thereby blocking the conversion of SPD to SPM. This invention clarifies the direct binding relationship and key binding sites between MTA and SMS, elucidating the technical basis for MTA inhibiting inflammatory signaling pathways and improving RPE / external blood-retinal barrier damage by inhibiting SMS and remodeling polyamine metabolism. It addresses the problems of existing intraocular inflammation treatments primarily relying on broad-spectrum immunosuppression, lacking metabolic target intervention, and struggling to simultaneously control inflammation and protect tissue barriers; providing a new direction for drug development for the precise intervention of intraocular inflammatory diseases, especially acute anterior uveitis and related acute intraocular inflammations.